IN181318B - - Google Patents

Info

Publication number
IN181318B
IN181318B IN100MA1996A IN181318B IN 181318 B IN181318 B IN 181318B IN 100MA1996 A IN100MA1996 A IN 100MA1996A IN 181318 B IN181318 B IN 181318B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN181318(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to IN100MA1996 priority Critical patent/IN181318B/en
Publication of IN181318B publication Critical patent/IN181318B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN100MA1996 1995-01-20 1996-01-19 IN181318B (he)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN100MA1996 IN181318B (he) 1995-01-20 1996-01-19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet
IN100MA1996 IN181318B (he) 1995-01-20 1996-01-19

Publications (1)

Publication Number Publication Date
IN181318B true IN181318B (he) 1998-05-09

Family

ID=10768317

Family Applications (1)

Application Number Title Priority Date Filing Date
IN100MA1996 IN181318B (he) 1995-01-20 1996-01-19

Country Status (39)

Country Link
US (1) US5879706A (he)
EP (1) EP0806943B1 (he)
JP (1) JP3350055B2 (he)
KR (1) KR100412298B1 (he)
CN (2) CN1313081C (he)
AP (1) AP666A (he)
AT (1) ATE190483T1 (he)
AU (1) AU710823B2 (he)
BG (1) BG63187B1 (he)
BR (1) BR9606769A (he)
CA (1) CA2210891C (he)
CY (1) CY2182B1 (he)
CZ (1) CZ296514B6 (he)
DE (1) DE69607146T2 (he)
DK (1) DK0806943T3 (he)
EA (1) EA000276B1 (he)
EE (1) EE03336B1 (he)
ES (1) ES2145425T3 (he)
FI (1) FI119722B (he)
GB (1) GB9501127D0 (he)
GE (1) GEP20022752B (he)
GR (1) GR3033677T3 (he)
HK (1) HK1002851A1 (he)
HU (1) HU226131B1 (he)
IL (1) IL116830A (he)
IN (1) IN181318B (he)
MY (1) MY126346A (he)
NO (1) NO311488B1 (he)
NZ (1) NZ298846A (he)
OA (1) OA10500A (he)
PL (1) PL185307B1 (he)
PT (1) PT806943E (he)
RO (1) RO118175B1 (he)
SK (1) SK282030B6 (he)
TR (1) TR199700657T1 (he)
UA (1) UA68325C2 (he)
UY (2) UY25774A1 (he)
WO (1) WO1996022082A1 (he)
ZA (1) ZA96448B (he)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
SI20624A (sl) * 1998-12-18 2002-02-28 Abbott Laboratories Formulacija divalproeks natrija za kontrolirano sproščanje
GB0010446D0 (en) 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
NZ528886A (en) * 2001-05-01 2005-04-29 Pfizer Prod Inc A dry process for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
ATE335743T1 (de) * 2002-10-16 2006-09-15 Teva Pharma Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
CA2527708A1 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
TR201910177T4 (tr) 2003-09-12 2019-08-21 Amgen Inc Bir sinakalset HCl içeren hızlı çözünme formülasyonu.
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
EP1541133B1 (en) * 2003-12-09 2005-08-10 Helm AG Pharmaceutical formulation of valaciclovir
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
MX2007010856A (es) 2005-03-07 2007-11-12 Bayer Healthcare Ag Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer.
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
JP2009536165A (ja) * 2006-05-10 2009-10-08 エボニック デグサ ゲーエムベーハー 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用
DE602007009230D1 (de) * 2006-05-31 2010-10-28 Vertex Pharma Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors
WO2008006534A2 (en) * 2006-07-11 2008-01-17 Lek Pharmaceuticals D.D. Multiple unit tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
DK2407166T3 (da) * 2009-03-13 2013-10-07 Toyama Chemical Co Ltd Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
BR112023009427A2 (pt) * 2020-12-01 2024-02-06 Lg Chemical Ltd Formulação oral que compreende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico e método de preparação da mesma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ATE82680T1 (de) * 1988-05-04 1992-12-15 Smith Kline French Lab Kautablette.
SK282071B6 (sk) * 1991-01-30 2001-10-08 The Wellcome Foundation Limited Tableta dispergovateľná vo vode a spôsob jej prípravy
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
GB9501127D0 (en) 1995-03-08
CY2182B1 (en) 2002-08-23
FI119722B (fi) 2009-02-27
KR19980701524A (ko) 1998-05-15
AU4453496A (en) 1996-08-07
KR100412298B1 (ko) 2004-04-21
ATE190483T1 (de) 2000-04-15
HK1002851A1 (en) 1998-09-25
AP666A (en) 1998-08-24
NO973327L (no) 1997-09-16
CZ296514B6 (cs) 2006-03-15
HU226131B1 (en) 2008-05-28
EP0806943A1 (en) 1997-11-19
MX9705459A (es) 1997-10-31
RO118175B1 (ro) 2003-03-28
TR199700657T1 (xx) 1998-02-21
HUP9801872A3 (en) 2001-02-28
PL185307B1 (pl) 2003-04-30
UA68325C2 (en) 2004-08-16
ZA96448B (en) 1996-08-07
DE69607146D1 (de) 2000-04-20
CN1179100A (zh) 1998-04-15
GR3033677T3 (en) 2000-10-31
NZ298846A (en) 1998-06-26
BG101831A (en) 1998-04-30
EA000276B1 (ru) 1999-02-25
JP3350055B2 (ja) 2002-11-25
UY25774A1 (es) 2000-10-31
CA2210891C (en) 2009-05-19
PL321361A1 (en) 1997-12-08
WO1996022082A1 (en) 1996-07-25
AU710823B2 (en) 1999-09-30
OA10500A (en) 2002-04-10
AP9701057A0 (en) 1997-10-31
ES2145425T3 (es) 2000-07-01
SK282030B6 (sk) 2001-10-08
FI973062A0 (fi) 1997-07-18
PT806943E (pt) 2000-08-31
EP0806943B1 (en) 2000-03-15
CN1313081C (zh) 2007-05-02
EA199700123A1 (ru) 1997-12-30
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
EE03336B1 (et) 2001-02-15
MY126346A (en) 2006-09-29
CZ229297A3 (cs) 1998-02-18
IL116830A0 (en) 1996-05-14
FI973062A (fi) 1997-09-18
UY25778A1 (es) 2000-08-21
DE69607146T2 (de) 2000-09-21
NO311488B1 (no) 2001-12-03
JPH10512564A (ja) 1998-12-02
CN1494898A (zh) 2004-05-12
SK96497A3 (en) 1998-01-14
NO973327D0 (no) 1997-07-18
BG63187B1 (bg) 2001-06-29
HUP9801872A2 (hu) 1999-10-28
DK0806943T3 (da) 2000-07-24
IL116830A (en) 2000-02-29
US5879706A (en) 1999-03-09
GEP20022752B (en) 2002-08-26
BR9606769A (pt) 1997-12-30

Similar Documents

Publication Publication Date Title
DE69638352D1 (he)
DE69637714D1 (he)
BRPI9612258B1 (he)
BRPI9612138B1 (he)
DK143195A (he)
CH0741373H1 (he)
DK0727898T3 (he)
IN181368B (he)
BR7502120U (he)
DK126096A (he)
AU1627395A (he)
BR7501503U (he)
IN182929B (he)
CN3032568S (he)
CN3034829S (he)
CN3031001S (he)
CN3031350S (he)
CN3031655S (he)
CN3031742S (he)
CN3031926S (he)
CN3032332S (he)
CN3032390S (he)
CN3032522S (he)
EP0959919A4 (he)
CN3030542S (he)